|Table of Contents|

Correlation of ARID1A gene mutation and MSH2 protein expression with clinicopathological characteristics and prognosis in colorectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 06
Page:
1068-1073
Research Field:
Publishing date:

Info

Title:
Correlation of ARID1A gene mutation and MSH2 protein expression with clinicopathological characteristics and prognosis in colorectal cancer
Author(s):
LAO Jingmao; DENG Wei; WEI Xiaobo; LIU Guang; JIAN Wenhong
Department of Gastrointestinal Surgery,Qinzhou First People's Hospital,Guangxi Qinzhou 535000,China.
Keywords:
colorectal neoplasms; gene mutation; AT-rich interactive domain 1A; mutS homologous 2; prognosis
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2023.06.016
Abstract:
Objective：To detect AT-rich interactive domain 1A (ARID1A) gene mutation and mutS homologous 2 (MSH2) protein expression in colorectal cancer (CRC) tissues,and to analyze their clinical significance.Methods:A total of 142 CRC patients diagnosed and treated in our hospital from January 2017 to January 2018 were selected as the research subjects.ARID1A gene mutations in cancer tissues were detected by direct sequencing.MSH2 protein expression in cancer and paracancerous tissue were detected by immunohistochemistry.The correlation between ARID1A gene mutation and MSH2 protein expression was analyzed by Spearman rank correlation analysis.The relationship between ARID1A gene mutation,MSH2 protein expression and clinicopathological features of CRC was statistically analyzed.The effects of ARID1A gene mutation and MSH2 protein expression on survival prognosis of patients were analyzed by Kaplan-Meier survival analysis.Factors affecting the survival prognosis of CRC patients were analyzed by univariate and multivariate Cox regression analysis.Results:Among the 142 CRC cancer tissues,27 had ARID1A gene mutation,and the ARID1A gene mutation rate was 19.01% (27/142).MSH2 brown-yellow positive expression was mainly located in the nucleus.The positive rate of MSH2 in CRC cancer tissues was 51.40% (73/142),which was significantly lower than that in paracancerous tissues,which was 91.55% (130/142) (χ2=56.116,P=0.000).The ARID1A gene mutation and MSH2 positive rate in different tumor TNM stages and lymph node metastasis CRC cancer tissues were significantly different (P＜0.05).There was a significant negative correlation between ARID1A gene mutation and MSH2 expression in CRC cancer tissues (r=-0.575,P=0.000).The 3-year overall survival rate of patients in ARID1A gene mutation group was 37.04% (10/27),which was significantly lower than 67.27% (74/110) in wild-type group (P=0.000).The 3-year overall survival rate of patients in MSH2 positive expression group was 81.43% (57/70),which was significantly higher than that in the negative expression group,which was 42.30% (27/67) (P=0.000).ARID1A gene mutation,MSH2 negative expression,tumor TNM stage III and lymph node metastasis were independent risk factors for the prognosis of CRC patients(P＜0.05).Conclusion:ARID1A gene and MSH2 expression are associated with tumor stage and lymph node metastasis in CRC patients,and are independent prognostic factors for CRC patients.

References:

［1］ BAIDOUN F,ELSHIWY K,ELKERAIE Y,et al.Colorectal cancer epidemiology:Recent trends and impact on outcomes［J］.Curr Drug Targets,2021,22(9):998-1009.
［2］ 高鑫,刘刚,张琦,等.结直肠癌肿瘤内异质性研究进展［J］.中华实验外科杂志,2020,37(9):1781-1784. GAO X,LIU G,ZHANG Q,et al.Advances in the study of intra-tumor heterogeneity in colorectal cancer［J］.Chinese Journal of Experimental Surgery,2020,37(9):1781-1784.
［3］ MULLEN J,KATO S,SICKLICK JK,et al.Targeting ARID1A mutations in cancer［J］.Cancer Treat Rev,2021,100(6):1022-1229.
［4］ MATHUR R.ARID1A loss in cancer:Towards a mechanistic understanding［J］.Pharmacol Ther,2018,190(9):15-23.
［5］ MCCOY P,MANGIOLA S,MACINTYRE G,et al.MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer［J］.Prostate Cancer Prostatic Dis,2021,24(4):1167-1180.
［6］ GE H,XIAO Y,QIN G,et al.Mismatch repair deficiency is associated with specific morphologic features and frequent loss of ARID1A expression in ovarian clear cell carcinoma［J］.Diagn Pathol,2021,16(1):12-21.
［7］ 田传鑫,赵磊.结直肠癌及结直肠癌肝转移流行病学特点［J］.中华肿瘤防治杂志,2021,28(13):1033-1038. TIAN CX,ZHAO L.Epidemiological characteristics of colorectal cancer and colorectal liver metastasis［J］.Chinese Journal of Cancer Prevention and Treatment,2021,28(13):1033-1038.
［8］ 钟丽萍,李丹,朱丽珍,等.西妥昔单抗治疗转移性结直肠癌患者预后列线图预测模型研究［J］.中华胃肠外科杂志,2020,23(7):701-708. ZHONG LP,LI D,ZHU LZ,et al.A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab［J］.Chinese Journal of Gastrointestinal Surgery,2020,23(7):701-708.
［9］ MALKI A,ELRUZ RA,GUPTA I,et al.Molecular mechanisms of colon cancer progression and metastasis:recent insights and advancements［J］.Int J Mol Sci,2020,22(1):130-138.
［10］ HELMING KC,WANG X,ROBERTS CWM.Vulnerabilities of mutant SWI/SNF complexes in cancer［J］.Cancer Cell,2014,26(3):309-317.
［11］ INTARAJAK T,UDOMCHAIPRASERTKUL W,BUNYOO C,et al.Genetic aberration analysis in thai colorectal adenoma and early-stage adenocarcinoma patients by whole-exome sequencing［J］.Cancers (Basel),2019,11(7):977-986.
［12］ TOKUNAGA R,XIU J,GOLDBERG RM,et al.The impact of ARID1A mutation on molecular characteristics in colorectal cancer［J］.Eur J Cancer,2020,140(7):119-129.
［13］ 潘思琼,陆奉科,李山.错配修复蛋白MLH1、MSH2、PMS2、MSH6及p53在结直肠癌中的表达及意义［J］.海南医学,2021,32(1):4-7. PAN SQ,LU FK,LI S.Expression and significance of mismatch repair proteins MLH1,MSH2,MSH6,PMS2,and p53 in colorectal cancer［J］.Hainan Medical Journal,2021,32(1):4-7.
［14］ NIELSEN SV,HARTMANN-PETERSEN R,STEIN A,et al.Multiplexed assays reveal effects of missense variants in MSH2 and cancer predisposition［J］.PLoS Genet,2021,17(4):1009496.
［15］ DONG L,ZHU Y,WU L,et al.Detection of 2 gene methylation in extramammary Paget's disease by methylation-sensitive high-resolution melting analysis［J］.J Oncol,2021,2021(7):5514.
［16］ CHEN H,GAO S,LIU W,et al.RNA N-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the mA-GLUT1-mTORC1 axis and is a therapeutic target［J］.Gastroenterology,2021,160(4):1284-1300.
［17］ ZHANG H,XIAO X,WEI W,et al.CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer［J］.Mol Cancer,2021,20(1):70-78.
［18］ KAWAKAMI H,ZAANAN A,SINICROPE FA.Microsatellite instability testing and its role in the management of colorectal cancer［J］.Curr Treat Options Oncol,2015,16(7):30-40.
［19］ FAN J,WANG G,CHENG X,et al.Relationship between mismatch repair protein,gene expression and clinicopathological characteristics in elderly colorectal cancer patients［J］.World J Clin Cases,2021,9(11):2458-2468.
［20］ CHOU A,TOON CW,CLARKSON A,et al.Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency［J］.Hum Pathol,2014,45(8):1697-1703.

Memo

Memo:
广西壮族自治区卫计委自筹经费科研课题（编号：Z20210329）
Last Update: 1900-01-01